Tenecteplase: A Review of Its Pharmacology and Uses

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

Many hospital systems are adding tenecteplase to the formulary or switching to tenecteplase as the thrombolytic of choice despite its lack of FDA approval for indications other than myocardial infarction.3-5 Institutions cite workflow advantages and potential cost savings with tenecteplase (the wholesale acquisition cost is $8071.39 per 50-mg vial of tenecteplase, as compared with $10 560.43 per 100-mg vial of alteplase).1,2 Therefore, it is imperative for all clinicians involved with the treatment of patients with myocardial infarction, ischemic stroke, or PE to understand the pharmacology, uses, and clinical evidence regarding tenecteplase.

Objectives

Discuss the pharmacology of tenecteplase.
Identify the key differences in dosing and administration of thrombolytics
Analyze the available literature for tenecteplase's use in acute ischemic stroke, pulmonary embolism, and acute myocardial infarction.

Continuing Education Disclosure Statement

Criteria for Awarding Contact Hours

Learners must complete the entire activity and the associated evaluation AND read Implicit Bias impacts patient outcomes. No partial credit will be awarded.

Accreditation

American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for {contactHours} contact hours.

Disclosures

The Nurse Planner has determined that no individuals with the ability to control content of this activity have relevant relationships with ineligible companies.

Activities with pharmacotherapeutic credit are to assist the APRN in fulfilling their education requirements for licensure and certification renewals.

Refund Policy

Continuing Education Activities are nonrefundable.